0102030405
Micafungin CAS No. 235114-32-6 Antifungal Pharmaceutical Raw Material
02
introduce
introduce
Micafungin is a semi-synthetic echinocandin antifungal and core pharmaceutical API, derived from the fermentation product of Coleophoma empetri. It specifically inhibits fungal cell wall β(1,3)-D-glucan synthesis (absent in mammalian cells), exhibiting potent activity against Candida spp. and Aspergillus spp.
Widely used in clinical antifungal therapy and biomedical research, our products comply with strict international standards to ensure high purity, stable efficacy, and reliable supply.
02
Physical and chemical properties
Micafungin exhibits key physical and chemical characteristics supporting its pharmaceutical and research applications, as follows:
- Melting Point: >198 °C
- Density: 1.6±0.1 g/cm³
- Storage: -20 °C, under inert atmosphere, sealed to prevent hygroscopicity
- Solubility: Slightly soluble in DMSO; very slightly soluble in heated methanol
- Stability: Hygroscopic; stable for 2 years under recommended storage conditions
- Melting Point: >198 °C
- Density: 1.6±0.1 g/cm³
- Storage: -20 °C, under inert atmosphere, sealed to prevent hygroscopicity
- Solubility: Slightly soluble in DMSO; very slightly soluble in heated methanol
- Stability: Hygroscopic; stable for 2 years under recommended storage conditions
1. Unique Mechanism of Action with Higher Safety
As an echinocandin antifungal, it exerts its effect by inhibiting the synthesis of 1,3-β-D-glucan in the fungal cell wall. Since human cells lack cell walls and this component, it does not cause severe side effects such as nephrotoxicity, unlike the traditional antifungal amphotericin B. Compared with triazole drugs (e.g., fluconazole), it has no significant risk of drug-drug interactions, resulting in better medication safety.
As an echinocandin antifungal, it exerts its effect by inhibiting the synthesis of 1,3-β-D-glucan in the fungal cell wall. Since human cells lack cell walls and this component, it does not cause severe side effects such as nephrotoxicity, unlike the traditional antifungal amphotericin B. Compared with triazole drugs (e.g., fluconazole), it has no significant risk of drug-drug interactions, resulting in better medication safety.
2. Antibacterial Spectrum Adapts to Core Clinical Needs
It has a fungicidal effect on most Candida strains, making up for fluconazole's ineffectiveness against Aspergillus species and exerting a clear fungistatic effect on various Aspergillus strains. It is also effective against the cyst form of Pneumocystis jirovecii. Its antibacterial spectrum covers common clinically opportunistic pathogenic fungi, with a wider range of applications than antifungal drugs with narrow spectra.
It has a fungicidal effect on most Candida strains, making up for fluconazole's ineffectiveness against Aspergillus species and exerting a clear fungistatic effect on various Aspergillus strains. It is also effective against the cyst form of Pneumocystis jirovecii. Its antibacterial spectrum covers common clinically opportunistic pathogenic fungi, with a wider range of applications than antifungal drugs with narrow spectra.
3. Low Resistance Risk and Strong Combination Compatibility
Fungal resistance to micafungin is extremely rare, which is superior to triazole drugs with cross-resistance issues. It can be combined with a variety of clinically commonly used drugs (such as the HIV protease inhibitor ritonavir, and transplant medications cyclosporine and tacrolimus), adapting to complex clinical treatment scenarios.
Its core application is antifungal treatment and prevention, suitable for infections caused by various fungi. The specific scenarios include:
1. Treatment of Candida-related Infections
Used for the treatment of candidemia, acute disseminated candidiasis, Candida peritonitis, abscesses, and esophageal candidiasis, especially effective for fluconazole-resistant Candida infections.
2. Prevention of Fungal Infections in High-risk Groups
Used to prevent Candida infections in hematopoietic stem cell transplant recipients, reducing the infection risk in these immunocompromised populations.
3. Treatment of Aspergillosis
It has a fungistatic effect on Aspergillus species and can be used to treat patients with aspergillosis who are intolerant to other antifungal therapies.
4. Other Antifungal Applications
Used for the treatment of candidemia, acute disseminated candidiasis, Candida peritonitis, abscesses, and esophageal candidiasis, especially effective for fluconazole-resistant Candida infections.
2. Prevention of Fungal Infections in High-risk Groups
Used to prevent Candida infections in hematopoietic stem cell transplant recipients, reducing the infection risk in these immunocompromised populations.
3. Treatment of Aspergillosis
It has a fungistatic effect on Aspergillus species and can be used to treat patients with aspergillosis who are intolerant to other antifungal therapies.
Effective against the cyst form of Pneumocystis jirovecii, it can be used as an adjuvant treatment for related infections. It should be noted that this drug has no inhibitory effect on fungi such as Cryptococcus, Fusarium, and Trichosporon.
We implement strict full-process quality control, with each batch of Micafungin undergoing rigorous testing of key indicators including purity , solubility, stability, protein binding rate, and microbial contamination to meet standards.
Equipped with a stable fermentation-semisynthesis supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including reconstitution guidance, formulation optimization, and post-sales technical support for clinical and research applications.
Equipped with a stable fermentation-semisynthesis supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including reconstitution guidance, formulation optimization, and post-sales technical support for clinical and research applications.
As a key echinocandin antifungal, Micafungin is a cornerstone in treating life-threatening invasive fungal infections, broad efficacy, excellent tolerability, and reliable supply capacity, we are committed to providing high-quality Micafungin API and professional services for global pharmaceutical companies, hospitals, and research institutions.
Choose our Micafungin to meet your needs in clinical antifungal therapy, pharmaceutical formulation, and biomedical research. Contact us for more product details and cooperation support.
Choose our Micafungin to meet your needs in clinical antifungal therapy, pharmaceutical formulation, and biomedical research. Contact us for more product details and cooperation support.